These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 11755227)

  • 1. Zonisamide has beneficial effects on Parkinson's disease patients.
    Murata M; Horiuchi E; Kanazawa I
    Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
    Murata M
    Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
    Ueda Y; Tokashiki S; Kanemaru A; Kojima T
    Biochem Biophys Res Commun; 2012 Nov; 428(3):401-4. PubMed ID: 23103374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I; Fukasaka J; Kochi K; Shimazu R;
    Mov Disord; 2015 Sep; 30(10):1343-50. PubMed ID: 26094993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.
    Ikeda K; Yanagihashi M; Miura K; Ishikawa Y; Hirayama T; Takazawa T; Kano O; Kawabe K; Mizumura N; Iwasaki Y
    J Neurol Sci; 2018 Aug; 391():5-9. PubMed ID: 30103971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zonisamide: a new drug for Parkinson's disease.
    Murata M
    Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.
    Oki M; Kaneko S; Morise S; Takenouchi N; Hashizume T; Tsuge A; Nakamura M; Wate R; Kusaka H
    Neurosci Res; 2017 Sep; 122():45-50. PubMed ID: 28577977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The discovery of an antiparkinsonian drug, zonisamide].
    Murata M
    Rinsho Shinkeigaku; 2010 Feb; 50(2):67-73. PubMed ID: 20196486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of zonisamide on resting tremor resistant to antiparkinsonian medication].
    Nakanishi I; Kohmoto J; Miwa H; Kondo T
    No To Shinkei; 2003 Aug; 55(8):685-9. PubMed ID: 13677302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
    Gluck MR; Santana LA; Granson H; Yahr MD
    J Neural Transm (Vienna); 2004 Jun; 111(6):713-24. PubMed ID: 15168218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapy of Parkinson's disease--up to date].
    Murata M
    Rinsho Shinkeigaku; 2008 Nov; 48(11):986-8. PubMed ID: 19198140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Discovery of an antiparkinsonian drug: zonisamide].
    Murata M
    Rinsho Shinkeigaku; 2010 Nov; 50(11):780-2. PubMed ID: 21921440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacologic treatment of Parkinson disease].
    Murata M
    Brain Nerve; 2009 Apr; 61(4):464-72. PubMed ID: 19378816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Montastruc JL; Fuell D
    Clin Neuropharmacol; 1996 Jun; 19(3):234-45. PubMed ID: 8726542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.
    Yamamura S; Ohoyama K; Nagase H; Okada M
    Neuropharmacology; 2009 Sep; 57(3):322-31. PubMed ID: 19482038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
    Grover ND; Limaye RP; Gokhale DV; Patil TR
    Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zonisamide for the treatment of Parkinson's disease.
    Miwa H
    Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies in the therapy of Parkinson's disease.
    Fahn S
    Adv Neurol; 1996; 69():477-86. PubMed ID: 8615168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.